NuVasive logo
NuVasive NUVA

Quarterly report 2023-Q2
added 08-02-2023

report update icon

NuVasive Income Statement 2011-2025 | NUVA

Annual Income Statement NuVasive

2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Market Cap

2.29 B 2.68 B 2.76 B 4.09 B 2.5 B 2.54 B 3.49 B 2.25 B 2.16 B 1.69 B 751 M 630 M

Shares

52 M 51.6 M 51.4 M 52 M 51.4 M 50.9 M 50.1 M 48.7 M 46.7 M 44.5 M 43.3 M 40.4 M

Historical Prices

44.1 52 53.7 77.1 50.1 48.9 70.8 46.1 46.3 37.4 17.2 15.5

Net Income

40.4 M -64.1 M -37.2 M 65.2 M 12.5 M 83 M 37.1 M 66.3 M -16.7 M 7.9 M 3.14 M -69.8 M

Revenue

1.2 B 1.14 B 1.05 B 1.17 B 1.1 B 1.03 B 962 M 811 M 762 M 685 M 620 M 541 M

Cost of Revenue

337 M 322 M 322 M 312 M 311 M 268 M 240 M - - - - -

Gross Profit

865 M 817 M 729 M 856 M 791 M 761 M 722 M 617 M 580 M 505 M 467 M 428 M

Interest Expense

-21.4 M -25.5 M -16.9 M -5.92 M -8.17 M -1.54 M -305 K 425 K -2.41 M 3.1 M 1.05 M 2.08 M

EBITDA

147 M 150 M 141 M 172 M 153 M 170 M 140 M 116 M 72.4 M 52.4 M 59.1 M 40.9 M

Operating Expenses

777 M 829 M 691 M 735 M 688 M 638 M 624 M 513 M 521 M 472 M 420 M 394 M

General and Administrative Expenses

634 M 610 M 547 M 611 M 576 M 540 M 534 M 465 M 470 M 420 M 372 M 347 M

All numbers in USD currency

Quarterly Income Statement NuVasive

2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

52.4 M 52.2 M 52.1 M 52.1 M 52 M 51.8 M 51.8 M 51.7 M 51.6 M 51.4 M 51.4 M 51.3 M 51.2 M 51.8 M 52.1 M 52.1 M 52 M 51.7 M 56.6 M 51.4 M 51.4 M 51.2 M 56.2 M 50.7 M 51.1 M 50.6 M 55.2 M 50.3 M 50 M 49.6 M 52.6 M 49 M 48.5 M 48 M 47.7 M 47 M 46.8 M 45.8 K 44.9 M 44.6 M 44.4 M 44 M 43.7 M 43.5 M 43.3 M 42.8 M 42.5 M 39.9 M 39.8 M 39.6 M

Net Income

7.36 M -1.01 M - -1.98 M -893 K 19.2 M - -21.6 M 1.8 M -7.51 M - 5.87 M -50 M 5.3 M 29.9 M 11 M 15 M 9.39 M 12.2 M 15.9 M 11.5 M -27.1 M 23.5 M 33.5 M 12.2 M 12.4 M 6.38 M 3.93 M 30.2 M -3.37 M 11.5 M 13 M 10.3 M 31.6 M 7.47 M -1.83 M -4.09 M -18.3 M 6.01 M 7.51 M -6.47 M 851 K -2.75 M 2.35 M 2.86 M 673 K -10 M -67.6 M 5.38 M 2.36 M

Revenue

318 M 308 M - 295 M 310 M 291 M - 271 M 295 M 271 M - 295 M 204 M 260 M 310 M 291 M 292 M 275 M 288 M 271 M 282 M 261 M 271 M 247 M 259 M 249 M - - - - - - - - - - - - 191 M 169 M 166 M 160 M 166 M 148 M 154 M 152 M - - - -

Cost of Revenue

89.5 M 86.4 M - 80.9 M 85.8 M 79.1 M - 88.7 M 78.3 M 71.8 M - 84.6 M 80.5 M 71.9 M - 77 M 77.6 M 74.5 M - 74.2 M 77.1 M 73.8 M - 65.5 M 66.2 M 61.4 M - - - - - - - - - - - - - - - - - - - - - - - -

Gross Profit

228 M 221 M - 214 M 225 M 212 M - 182 M 217 M 199 M - 211 M 123 M 188 M 227 M 214 M 215 M 200 M 202 M 197 M 205 M 187 M 196 M 182 M 193 M 188 M 204 M 180 M 176 M 161 M 164 M 151 M 154 M 147 M 158 M 142 M 146 M 134 M 141 M 126 M 117 M 120 M 124 M 111 M 118 M 115 M 113 M 107 M 107 M 101 M

Interest Expense

-826 K -4.44 M - -21.1 M -29.7 M 16.2 M - -13.1 M 1.27 M -12.5 M - 251 K -11.7 M -7.41 M - -5.7 M 9 K -366 K - 4.24 M -2.38 M -9.7 M - -139 K -501 K 258 K - 94 K -246 K 50 K - 387 K -281 K 424 K - -2.49 M -205 K 375 K - 3.14 M -440 K 240 K - 260 K -551 K 437 K - 1.73 M 80 K 497 K

EBITDA

8 M 33.5 M - 110 M 13.4 M 36.8 M - 112 M 15.9 M 36.4 M - 106 M 70.1 M 35 M - 101 M 67.6 M 34.1 M - 96.4 M 64.2 M 32.1 M - 88.9 M 58.7 M 29.5 M - 73.8 M 46.3 M 21.2 M - 49 M 32.6 M 16.1 M - 46.5 M 31 M 15.4 M - 46.3 M 30.3 M 14.6 M - 38.2 M 25.3 M 12.1 M - 24.8 M 15.9 M 7.78 M

Operating Expenses

210 M 214 M - 193 M 192 M 200 M - 189 M 206 M 187 M - 184 M 160 M 160 M - 183 M 184 M 180 M - 179 M 176 M 205 M - 151 M 164 M 165 M - 159 M 116 M 149 M - 123 M 129 M 91.2 M - 126 M 141 M 162 M - 114 M 117 M 114 M - 98.1 M 105 M 108 M - 198 M 96 M 96.3 M

General and Administrative Expenses

164 M 176 M - 154 M 161 M 160 M - 146 M 157 M 146 M - 146 M 126 M 130 M - 153 M 153 M 145 M - 141 M 146 M 147 M - 126 M 139 M 140 M - 132 M 134 M 125 M - 111 M 115 M 116 M - 114 M 117 M 118 M - 102 M 104 M 99.9 M - 87.4 M 92.6 M 94.7 M - 85.5 M 84.3 M 84.2 M

All numbers in USD currency

The income statement is one of the three key financial reports of a company NuVasive (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:

  • How much revenue the company earned
  • How much it spent on production, personnel, marketing, taxes, etc.
  • What profit remained in the end

Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.

Features
  • The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
  • Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
  • A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.

Reports on the profits and losses of other stocks in the Medical devices industry

Issuer Price % 24h Market Cap Country
Apyx Medical Corporation Apyx Medical Corporation
APYX
$ 3.86 -3.26 % $ 134 M usaUSA
BioSig Technologies BioSig Technologies
BSGM
- 37.08 % $ 85.7 M usaUSA
Abiomed Abiomed
ABMD
- - $ 17.2 B usaUSA
GenMark Diagnostics, Inc. GenMark Diagnostics, Inc.
GNMK
- - $ 1.77 B usaUSA
Cutera Cutera
CUTR
- -10.19 % $ 1.99 M usaUSA
Lianluo Smart Limited Lianluo Smart Limited
LLIT
- 24.59 % $ 44.8 M chinaChina
Eargo Eargo
EAR
- - $ 10.2 M usaUSA
Obalon Therapeutics, Inc. Obalon Therapeutics, Inc.
OBLN
- -5.86 % $ 30.6 M usaUSA
Bio-Rad Laboratories Bio-Rad Laboratories
BIO
$ 307.92 -1.93 % $ 8.69 B usaUSA
Apollo Endosurgery Apollo Endosurgery
APEN
- - $ 475 M usaUSA
Acutus Medical Acutus Medical
AFIB
- -26.83 % $ 2.62 M usaUSA
Bruker Corporation Bruker Corporation
BRKR
$ 45.13 -2.67 % $ 6.72 K usaUSA
Allied Healthcare Products Allied Healthcare Products
AHPI
- 3.58 % $ 2.21 M usaUSA
Conformis Conformis
CFMS
- - $ 16.4 M usaUSA
Abbott Laboratories Abbott Laboratories
ABT
$ 125.1 1.48 % $ 218 B usaUSA
Boston Scientific Corporation Boston Scientific Corporation
BSX
$ 92.34 0.64 % $ 136 B usaUSA
CryoLife, Inc. CryoLife, Inc.
CRY
- -4.14 % $ 702 M usaUSA
EDAP TMS S.A. EDAP TMS S.A.
EDAP
$ 2.56 8.94 % $ 95.5 M franceFrance
Invacare Corporation Invacare Corporation
IVC
- - $ 24.7 M usaUSA
Cardiovascular Systems Cardiovascular Systems
CSII
- 0.15 % $ 844 M usaUSA
IRIDEX Corporation IRIDEX Corporation
IRIX
$ 0.92 -4.72 % $ 14.8 M usaUSA
CHF Solutions, Inc. CHF Solutions, Inc.
CHFS
- 1.15 % $ 34.5 M usaUSA
IRadimed Corporation IRadimed Corporation
IRMD
$ 96.35 -1.06 % $ 1.22 B usaUSA
OrthoPediatrics Corp. OrthoPediatrics Corp.
KIDS
$ 17.7 -3.46 % $ 408 M usaUSA
Soliton, Inc. Soliton, Inc.
SOLY
- -1.42 % $ 435 M usaUSA
Hancock Jaffe Laboratories, Inc. Hancock Jaffe Laboratories, Inc.
HJLI
- -1.98 % $ 98.3 M usaUSA
Itamar Medical Ltd. Itamar Medical Ltd.
ITMR
- 0.03 % $ 1.58 B israelIsrael
Misonix, Inc. Misonix, Inc.
MSON
- - $ 462 M usaUSA
Neovasc Neovasc
NVCN
- - $ 111 M canadaCanada
LivaNova PLC LivaNova PLC
LIVN
$ 62.79 -1.82 % $ 3.41 B britainBritain
Pulmonx Corporation Pulmonx Corporation
LUNG
$ 2.53 0.86 % $ 99 M usaUSA
Dynatronics Corporation Dynatronics Corporation
DYNT
- 14.99 % $ 929 K usaUSA
Intersect ENT, Inc. Intersect ENT, Inc.
XENT
- - $ 955 M usaUSA
InMode Ltd. InMode Ltd.
INMD
$ 14.56 0.76 % $ 1.15 B israelIsrael
Cognyte Software Ltd. Cognyte Software Ltd.
CGNT
$ 9.88 0.05 % $ 709 M israelIsrael
Myomo Myomo
MYO
$ 1.06 -1.85 % $ 7.47 M usaUSA
Second Sight Medical Products Second Sight Medical Products
EYES
- -0.97 % $ 54.4 M usaUSA
Integra LifeSciences Holdings Corporation Integra LifeSciences Holdings Corporation
IART
$ 13.41 -4.56 % $ 1.03 B usaUSA
Align Technology Align Technology
ALGN
$ 165.15 0.78 % $ 12.4 B usaUSA
Accuray Incorporated Accuray Incorporated
ARAY
$ 1.07 -3.18 % $ 110 M usaUSA
Avinger Avinger
AVGR
- -20.74 % $ 369 K usaUSA
ClearPoint Neuro ClearPoint Neuro
CLPT
$ 12.81 -1.23 % $ 346 M usaUSA
Orthofix Medical Orthofix Medical
OFIX
$ 15.51 -1.27 % $ 591 M curacaoCuracao
FONAR Corporation FONAR Corporation
FONR
$ 14.86 -0.03 % $ 97.4 M usaUSA
AxoGen AxoGen
AXGN
$ 30.33 1.15 % $ 1.34 B usaUSA
Axonics Modulation Technologies Axonics Modulation Technologies
AXNX
- - $ 3.31 B usaUSA
GBS GBS
GBS
- -0.57 % $ 7.12 M usaUSA
CONMED Corporation CONMED Corporation
CNMD
$ 40.78 2.33 % $ 1.26 B usaUSA
LENSAR LENSAR
LNSR
$ 11.48 -0.17 % $ 132 M usaUSA